Chemed Corporation reported consolidated net income of $146.7 million for the most recent period, compared to $119.3 million in the prior comparable period and a net loss of $54.4 million in an earlier period. For the three months ended September 30, 2025, Chemed recorded consolidated net income of $64.2 million, with VITAS contributing $46.8 million and Roto-Rooter $32.1 million, while the corporate segment showed a loss of $14.6 million. Adjusted EBITDA for the latest period was $123.0 million, with VITAS generating $70.9 million, Roto-Rooter $56.4 million, and the corporate segment a negative $4.3 million. Significant items affecting net income included stock option expense of $23.9 million, long-term incentive compensation of $15.8 million, amortization of reacquired franchise agreements of $7.1 million, and acquisition expenses totaling $1.3 million. Business developments during the reported periods included continued activities in both the VITAS and Roto-Rooter segments, with ongoing expenses related to stock options, incentive compensation, and acquisitions. The company highlighted risks and uncertainties that may impact future results.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemed Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000019584-25-000006), on October 31, 2025, and is solely responsible for the information contained therein.
Comments